Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s42003-021-02029-w http://scihub22266oqcxt.onion/10.1038/s42003-021-02029-w 33893388!8065039!33893388     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Commun+Biol 2021 ; 4 (1): 500 Nephropedia Template TP {{tp|p=33893388|t=2021. Structure and function analysis of a potent human neutralizing antibody CA521(FALA) against SARS-CoV-2 |pdf=|usr=}}{{33893388}} gab.com Text Structure and function analysis of a potent human neutralizing antibody CA521(FALA) against SARS-CoV-2 JO: Commun Biol http://www.kidney.de/pget.php?&tw=1&pmid=33893388 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic, which has resulted in more than two million deaths at 2021 February . There is currently no approved therapeutics for treating COVID-19. The SARS-CoV-2 Spike protein is considered a key therapeutic target by many researchers. Here we describe the identification of several monoclonal antibodies that target SARS-CoV-2 Spike protein. One human antibody, CA521(FALA), demonstrated neutralization potential by immunizing human antibody transgenic mice. CA521(FALA) showed potent SARS-CoV-2-specific neutralization activity against SARS-CoV-2 pseudovirus and authentic SARS-CoV-2 infection in vitro. CA521(FALA) also demonstrated having a long half-life of 9.5 days in mice and 9.3 days in rhesus monkeys. CA521(FALA) inhibited SARS-CoV-2 infection in SARS-CoV-2 susceptible mice at a therapeutic setting with virus titer of the lung reduced by 4.5 logs. Structural analysis by cryo-EM revealed that CA521(FALA) recognizes an epitope overlapping with angiotensin converting enzyme 2 (ACE2)-binding sites in SARS-CoV-2 RBD in the Spike protein. CA521(FALA) blocks the interaction by binding all three RBDs of one SARS-CoV-2 spike trimer simultaneously. These results demonstrate the importance for antibody-based therapeutic interventions against COVID-19 and identifies CA521(FALA) a promising antibody that reacts with SARS-CoV-2 Spike protein to strongly neutralize its activity. Twit Text FOAVip Structure and function analysis of a potent human neutralizing antibody CA521(FALA) against SARS-CoV-2 ????Commun Biol http://www.kidney.de/pget.php?&tw=1&pmid=33893388 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33893388 #FOAvip English Wikipedia <ref>{{Cite pmid|33893388}}</ref> Structure and function analysis of a potent human neutralizing antibody CA521(FALA) against SARS-CoV-2 #MMPMID33893388 Song D; Wang W; Dong C; Ning Z; Liu X; Liu C; Du G; Sha C; Wang K; Lu J; Sun B; Zhao Y; Wang Q; Xu H; Li Y; Shen Z; Jiao J; Wang R; Tian J; Liu W; Wang L; Deng YQ; Dou C Commun Biol 2021[Apr]; 4 (1): 500 PMID33893388show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic, which has resulted in more than two million deaths at 2021 February . There is currently no approved therapeutics for treating COVID-19. The SARS-CoV-2 Spike protein is considered a key therapeutic target by many researchers. Here we describe the identification of several monoclonal antibodies that target SARS-CoV-2 Spike protein. One human antibody, CA521(FALA), demonstrated neutralization potential by immunizing human antibody transgenic mice. CA521(FALA) showed potent SARS-CoV-2-specific neutralization activity against SARS-CoV-2 pseudovirus and authentic SARS-CoV-2 infection in vitro. CA521(FALA) also demonstrated having a long half-life of 9.5 days in mice and 9.3 days in rhesus monkeys. CA521(FALA) inhibited SARS-CoV-2 infection in SARS-CoV-2 susceptible mice at a therapeutic setting with virus titer of the lung reduced by 4.5 logs. Structural analysis by cryo-EM revealed that CA521(FALA) recognizes an epitope overlapping with angiotensin converting enzyme 2 (ACE2)-binding sites in SARS-CoV-2 RBD in the Spike protein. CA521(FALA) blocks the interaction by binding all three RBDs of one SARS-CoV-2 spike trimer simultaneously. These results demonstrate the importance for antibody-based therapeutic interventions against COVID-19 and identifies CA521(FALA) a promising antibody that reacts with SARS-CoV-2 Spike protein to strongly neutralize its activity. |Angiotensin-Converting Enzyme 2/immunology/metabolism[MESH] |Animals[MESH] |Antibodies, Monoclonal/immunology/*pharmacology[MESH] |Antibodies, Neutralizing/immunology/*pharmacology[MESH] |COVID-19/epidemiology/*prevention & control/virology[MESH] |Humans[MESH] |Male[MESH] |Mice[MESH] |Mice, Inbred C57BL[MESH] |Mice, Transgenic[MESH] |Pandemics[MESH] |Protein Binding/drug effects[MESH] |Receptors, Virus/immunology/metabolism[MESH] |SARS-CoV-2/*immunology/metabolism/physiology[MESH]Structure and function analysis of a potent human neutralizing antibod(epmc).pdf DeepDyve Pubget Overpricing